-
WilmerHale Advises Datanomix in $12M Growth Capital
5.12.2023Gary Schall, Elijah Soko and Cindy Sullivan advised Datanomix in its recently announced financing round.
-
2023 M&A Report
3.31.2023The 2023 M&A Report provides a broad, global M&A market review and outlook, plus insights on several important topics.
-
2023 Venture Capital Report
3.31.2023The 2023 Venture Capital Report offers an in-depth US venture capital market review and outlook, including regional and industry breakdowns, along with insights on key topics.
-
2023 IPO Report
3.31.2023The 2023 IPO Report shares a detailed look at the IPO market and provides useful market metrics and need-to-know information on topics that affect pre-IPO companies.
-
2023 IPO, Venture Capital and M&A Reports
3.31.2023WilmerHale’s annual IPO, Venture Capital and M&A reports offer detailed insights into market conditions and provide comprehensive statistics and thoughtful analysis.
-
Recent Venture Financings as Company Counsel: 2023
3.9.2023In 2022, we served as counsel in more than 200 venture financings raising over $7 billion, including some of the largest and most prominent deals of the year.
-
WilmerHale Represents Volastra Therapeutics in $60M Series A Financing
3.9.2023WilmerHale represented Volastra Therapeutics, a clinical stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), in closing its $60 million Series A financing, which was led by founding investors Polaris Partners and ARCH Venture Partners alongside Eli Lilly and Company.
-
WilmerHale Advises Dalia on Series A Financing
2.1.2023Dalia, a recruitment marketing automation platform, announced the completion of its Series A financing round led by Lewis & Clark Ventures.
-
WilmerHale Advises Wellington Management in MBX Biosciences’ $115M Series B Financing
12.8.2022On November 14, MBX Biosciences, a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, announced the closing of a $115 million Series B financing round led by Wellington Management, which was represented by WilmerHale.
-
WilmerHale Advises Wellington Management in AMP Robotics’ $91M Series C Financing
12.8.2022On November 2, 2022, AMP Robotics, a pioneer in artificial intelligence, robotics, and infrastructure for the waste and recycling industry, announced it has raised $91 million in corporate equity in a Series C financing, led by Congruent Ventures and Wellington Management.
-
WilmerHale Advises Foodology in $50M Financing
11.21.2022Foodology, a Colombia-based virtual restaurant company, announced that it has raised $50 million in new funding, comprised of $20 million in equity and $30 million in debt.
-
WilmerHale Advises Metrist in Raising $5.5M in its Seed Round
11.21.2022On November 1, 2022, Metrist, a startup that helps IT teams stay on top of outages among the many cloud services they use to run their own applications, announced that it has raised a $5.5 million seed round.
-
WilmerHale Advises Quinio in $40M Financing
11.17.2022Quinio Holdings Limited, an e-commerce aggregator focused on Latin America, announced that it secured $40 million in new equity and debt financing.
-
WilmerHale Represents Alethea in Series A Financing Round
11.4.2022On November 2, 2022, Alethea announced that it raised $10 million in its Series A round led by Ted Schlein and Kevin Mandia of Ballistic Ventures.
-
WilmerHale Advises Equii in $6M Seed Funding Led by Khosla Ventures
9.30.2022On September 30, 2022, Cella Farms, Inc. D/B/A Equii, raised $6 million in seed funding from Khosla Ventures. Equii is a start-up food-tech company that is pioneering microbial protein technology by fermenting grains to create nutritionally complete high protein flours.
